The latest market prices and trends of Teclistamab-cqyv

Teritusumab (Teclistamab-cqyv) is one of the first bispecific antibodies approved for relapsed or refractory multiple myeloma (MM). Due to its mechanism and efficacy, it has attracted much attention in the field of global cancer treatment. By simultaneously targeting BCMA and CD3, it guides T cells directly to cancerous plasma cells to achieve precise killing. This mechanism is different from traditional chemotherapy or single-target inhibitors, giving it significant advantages in immune evasion and drug resistance.

From a clinical perspective, the biggest benefit of teritusumab is “precision and durability.” The drug reduces the number of myeloma cells, helping patients stay in remission longer and improve their overall quality of life. It does not require stem cell transplantation or chemotherapy support, can be administered via subcutaneous injection, and is well tolerated by patients. Because it is a targeted immune-binding drug, it is particularly important for specific groups of people, such as patients with relapse or failure of multiple lines of treatment. Teritusumab not only activates T cells to eliminate cancer cells, but also maintains immune activity and reduces tumor cell regeneration, giving patients hope for long-term disease control.

Currently, the generic drug teritusumab has been officially launched in China under the name "Teleco", but it has not yet been included in the national medical insurance and is a self-paid drug. According to market conditions, the price in domestic pharmacies ranges from RMB 30,000 to RMB 40,000 per box, and the price is related to the specifications. In overseas markets, the price of the European version of the original drug is slightly different. Each box of 30mg/3ml is about RMB 10,000, while the price of each box of 153mg/1.7ml (90mg/ml) is about RMB 50,000. Prices may vary in different countries due to taxes and exchange rate fluctuations. There are currently no generic versions of drugs on the market, and the global market is still dominated by original drugs.

Reference materials:https://www.tecvayli.com/